The ability of mesenchymal stem cells (MSCs) to modulate immune responses inspired a series of clinical trials addressing oral mucosal inflammation. We previously reported on the safety and efficacy of fresh, allogeneic and autologous, adipose-derived mesenchymal stem cells (ASCs) to treat feline gingivostomatitis (FCGS), an oral mucosal inflammatory disease that shares similarities with human oral lichen planus. To meet clinical demand and goals for future commercialization, we determined the feasibility of shipping fresh ASCs to distant clinics and extended our pilot studies to expand safety and efficacy data for shipped and non-shipped ASCs in a cohort of 18 FCGS cats enrolled locally and at a few different locations within the USA. We found that ASCs retained their viability, phenotype, and function after shipment. ASCs administered systemically resulted in a 72% positive response rate, identical to that noted in our previous studies. Cats that responded to ASC therapy had a significant decrease in circulating globulin concentration and histological evidence of decreased CD3+ T cells and CD20+ B cells in the oral mucosa. Responder cats also had significantly decreased percentages of CD8lo cells in blood prior to and at 3 months post-ASC therapy. CD8lo cells may serve as a potential “predictor” for response to systemic ASC therapy. Fresh feline ASCs can be successfully shipped and administered to cats with FCGS. ASCs modulate the immune response and demonstrate efficacy for chronic oral mucosal inflammatory lesions that are characterized by CD8+ T cell inflammation and T cell activation. FCGS is a potentially useful naturally occurring large animal model of human oral inflammatory diseases.

中文翻译：

---

使用脂肪来源的间充质干细胞疗法治疗患有慢性无反应性牙龈口炎的猫的多中心经验。

间充质干细胞（MSC）调节免疫反应的能力激发了一系列针对口腔粘膜炎症的临床试验。我们之前曾报道过新鲜，同种异体和自体，脂肪来源的间充质干细胞（ASC）治疗猫齿龈炎（FCGS）的安全性和有效性，该病是一种与人类口腔扁平苔藓相似的口腔粘膜炎性疾病。为了满足临床需求和未来商业化的目标，我们确定了将新鲜的ASC运送到遥远的诊所的可行性，并扩展了我们的试点研究，以扩大在本地和当地招募的18只FCGS猫的队列中运输和未运送的ASC的安全性和有效性数据。美国境内的几个不同地点。我们发现，ASC在运输后仍保留了其生存能力，表型和功能。系统地给予ASC可使阳性反应率达到72％，与我们之前的研究相同。对ASC治疗有反应的猫的循环球蛋白浓度显着降低，并且口腔黏膜中CD3 + T细胞和CD20 + B细胞减少的组织学证据。在ASC治疗之前和之后3个月，响应者猫的血液中CD8lo细胞百分比也显着降低。CD8lo细胞可能充当对系统性ASC治疗反应的潜在“预测因子”。新鲜的猫科动物ASC可以成功运送到FCGS并用在猫身上。ASC调节免疫应答并证明对以CD8 ​​+ T细胞炎症和T细胞活化为特征的慢性口腔粘膜炎性病变的功效。